Skip to content
10-Q

Quarterly Report

VOR BIOPHARMA INC. VOR

0001193125-26-220689

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 54.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 43.01M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 6.24M sh
Capex Q1 2026 · Mar 31, 2026 $48K
Capex Q1 2026 · Mar 31, 2025 $231K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$38.25M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$31.07M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $169.87M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $396.49M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $50.05M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$150.42M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$164.31M
Stockholders Equity Q1 2026 · Mar 31, 2025 $66.07M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$96.66M
Current Liabilities Q1 2026 · Mar 31, 2026 $16.08M
Current Liabilities Q1 2026 · Dec 31, 2025 $25.17M
Total Liabilities Q1 2026 · Mar 31, 2026 $657.17M
Total Liabilities Q1 2026 · Dec 31, 2025 $628.44M
Current Assets Q1 2026 · Mar 31, 2026 $500.78M
Current Assets Q1 2026 · Dec 31, 2025 $458.11M
Total Assets Q1 2026 · Mar 31, 2026 $506.75M
Total Assets Q1 2026 · Dec 31, 2025 $464.13M
Eps Diluted Q1 2026 · Mar 31, 2026 −$5.11
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$5.21
Eps Basic Q1 2026 · Mar 31, 2026 −$5.11
Eps Basic restated Q1 2026 · Mar 31, 2025 −$5.21
Sga Expense Q1 2026 · Mar 31, 2026 $17.57M
Sga Expense Q1 2026 · Mar 31, 2025 $6.59M
Rd Expense Q1 2026 · Mar 31, 2026 $17.6M
Rd Expense Q1 2026 · Mar 31, 2025 $26.7M
Net Income Q1 2026 · Mar 31, 2026 −$219.59M
Net Income Q1 2026 · Mar 31, 2025 −$32.49M
Operating Income Q1 2026 · Mar 31, 2026 −$35.16M
Operating Income Q1 2026 · Mar 31, 2025 −$33.29M